Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial

BACKGROUND: Tralokinumab is a fully human monoclonal antibody that specifically neutralizes interleukin‐13, a key driver of atopic dermatitis (AD). OBJECTIVES: To evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids (TCS) in patients with moderate‐to‐severe AD...

Descripción completa

Detalles Bibliográficos
Autores principales: Silverberg, J.I., Toth, D., Bieber, T., Alexis, A.F., Elewski, B.E., Pink, A.E., Hijnen, D., Jensen, T.N., Bang, B., Olsen, C.K., Kurbasic, A., Weidinger, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986183/
https://www.ncbi.nlm.nih.gov/pubmed/33000503
http://dx.doi.org/10.1111/bjd.19573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986183/
https://www.ncbi.nlm.nih.gov/pubmed/33000503
http://dx.doi.org/10.1111/bjd.19573

Ejemplares similares